Expertise in
8
conditions

Dr. Anca D. Askanase

Rheumatology
CUIMC/Herbert Irving Pavilion
161 Fort Washington Ave, 
New York, NY 
Offers Telehealth
Referral may be required
Before you request
Expertise in
8
conditions
CUIMC/Herbert Irving Pavilion
161 Fort Washington Ave, 
New York, NY 

Overview

Anca Askanase is a Rheumatologist practicing medicine in New York, New York.

Dr. Askanase is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Undifferentiated Connective Tissue Disease (UCTD), and Cutaneous Lupus Erythematosus (CLE).

She is actively involved in clinical research, co-authoring 184 peer reviewed articles and participating in 6 clinical trials.

Specialties

Rheumatology

Licenses

Internal Medicine in NY

Hospital Affiliations

New York-Presbyterian Hospital
Hospital For Special Surgery

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

CUIMC/Herbert Irving Pavilion
161 Fort Washington Ave, New York, NY 10032
Other Locations
ColumbiaDoctors - Midtown
51 W 51st St, New York, NY 10019

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: May 06, 2026
Intervention Type: Drug
Study Drug: JBT-101
Study Phase: Phase 2
Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis.
Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis.
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: CellCept, ACTHar Gel
Study Phase: Phase 4
Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
Enrollment Status: Terminated
Publish Date: February 27, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Enrollment Status: Completed
Publish Date: December 01, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 5 Less Clinical Trials

184 Total Publications

Targeting IL-1 in SLE-Associated Recurrent Pericarditis: A Case Series and Review of Mechanistic Rationale.
Targeting IL-1 in SLE-Associated Recurrent Pericarditis: A Case Series and Review of Mechanistic Rationale.
Journal: Journal of cardiovascular pharmacology
Published: August 19, 2026
Similar Doctors
Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required
Before you request

HSS - Belaire Building

525 East 71st Street, 7th Floor, 
New York, NY 
 (5.2 miles away)
212-860-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Spiera is a Rheumatologist practicing medicine in New York, New York. Dr. Spiera is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Systemic Sclerosis (SSc), Vasculitis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica. Dr. Spiera is currently accepting new patients.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required
Before you request

Hospital For Special Surgery-Main Hospital

535 E 70th St Fl 6, 
New York, NY 
 (5.0 miles away)
212-606-1163
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Susan Goodman is a Rheumatologist practicing medicine in New York, New York. Dr. Goodman is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Rheumatoid Arthritis (RA), Arthritis, Psoriatic Arthritis, Knee Replacement, and Hip Replacement.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required
Before you request

Gramercy Park Physicians LLP

10 Union Sq E, 
New York, NY 
 (7.7 miles away)
212-844-8800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alice Gottlieb is a Rheumatologist practicing medicine in New York, New York. Dr. Gottlieb is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Psoriasis, Psoriatic Arthritis, Plaque Psoriasis, and Arthritis. Dr. Gottlieb is currently accepting new patients.

Frequently Asked Questions about Dr. Anca D. Askanase

How do I make an appointment with Dr. Anca D. Askanase?

You can book an appointment with Dr. Anca D. Askanase by calling their office at 929-445-7376. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anca D. Askanase a top-rated expert for Systemic Lupus Erythematosus (SLE)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anca D. Askanase is classified as an Elite expert for Systemic Lupus Erythematosus (SLE), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anca D. Askanase specialize in?

While Dr. Anca D. Askanase is a Rheumatology, they have specific expertise in Systemic Lupus Erythematosus (SLE), Lupus Nephritis, and Undifferentiated Connective Tissue Disease (UCTD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Anca D. Askanase participate in research or clinical trials?

Yes. Dr. Anca D. Askanase has published 184 articles and abstracts on conditions like Systemic Lupus Erythematosus (SLE). You can view a list of Dr. Anca D. Askanase's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anca D. Askanase accept my insurance?

Dr. Anca D. Askanase accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 929-445-7376 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Askanase's expertise for a condition
ConditionClose
View All 44 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile